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Abstract 
Aim 
To investigate muscle stiffness changes in patients treated for giant cell arteritis (GCA) 
with high-dose oral glucocorticoids. 
Methods  
Using ultrasound elastography, shear wave velocity (SWV) was measured in the 
quadriceps, hamstrings and biceps brachii muscles of 14 patients with GCA (4 males, 
mean age(±SD) 68.2±4.3 years) within the first 2 weeks of initiating glucocorticoid 
treatment (baseline) and repeated after 3 and 6 months treatment. Muscle strength 
and performance tests were performed at each visit. Baseline measures were 
compared with those from 14 healthy controls. Linear mixed models were used to test 
for change in patient measures over time. 
Results  
At baseline, muscle SWV in patients was not significantly different to controls. With 
glucocorticoid treatment, there was a reduction in SWV in the leg but not the arm 
muscles. SWV decreased by a mean of 14% (range 8.3%–17.3%; p=0.001) after 3 
months and 18% (range 10.2%–25.3%; p<0.001) after 6-months in the quadriceps and 
hamstrings during the resting position. The baseline, 3-months and 6-months mean 
SWV(±SD) for the vastus lateralis were 1.62±0.16m/s, 1.40±0.10m/s and 
1.31±0.06m/s respectively (p<0.001). In the patient group as a whole, there was no 
significant change in muscle strength. However, there were moderate correlations 
(r=0.54–0.69) between exhibiting weaker muscle strength at follow-up visits and a 
greater reduction in SWV.  
Conclusion 
Glucocorticoid therapy in patients with GCA was associated with a significant 
reduction in proximal leg muscle stiffness during the first 6 months. Future research 
should study a larger sample of patients for a longer duration to investigate if 
diminished muscle stiffness precedes signs of glucocorticoid-induced myopathy. 
Key words: Elasticity Imaging Techniques; Diagnostic Imaging; Muscles; 
Glucocorticoids; Giant Cell Arteritis, Muscular Diseases.  
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Introduction 
Glucocorticoid therapy is commonly used for a range of medical conditions due to 
its powerful anti-inflammatory and immunosuppressive effects. However, despite their 
efficacy, they are linked to numerous adverse events, which have been estimated to 
cost the UK at least £165 per patient annually to manage 1. This paper study focuses 
on glucocorticoid induced myopathy (GIM), a non-inflammatory condition affecting 
largely the proximal muscles and associated with muscle weakness, wasting and 
fatigability. Glucocorticoids, irrespective of the route administered (inhaled, oral or 
intra-venous), have shown to be associated with myopathy 2-7. The mechanisms of 
GIM have been linked to the decline in protein synthesis (anti-anabolic action)  and the 
rise in the catabolic rate of protein breakdown (catabolic action) 8. These mechanisms 
can consequently lead to the loss of muscle strength and mass 7.  
In rheumatology, glucocorticoids are the backbone of the management for a 
number of inflammatory-mediated disorders. In many cases, they are used only for 
short periods and at a relatively low dose. However, more serious conditions such as 
giant cell arteritis (GCA) require much higher doses and for longer periods of more 
than six months. Proven et al.9 prospectively assessed 125 GCA patients for muscle 
weakness (based on the physician’s diagnosis supported by physical examination of 
proximal muscles) and reported that “most patients” developed muscle weakness 
(exact incidence and severity were not mentioned). Currently, the identification of 
muscle involvement is largely based on patient reported symptoms and physical 
evidence of weakness in the hip girdle and proximal thigh muscles using manual 
muscle testing methods 10, 11. However, the diagnosis and monitoring of GIM may be 
challenging as these features may be non-specific and poorly sensitive to change.  
A recent review by Minetto et al. 10 has highlighted the importance of quantitative 
tests and the lack of predictive and prognostic tools for the steroid myopathic process. 
The available tests are either invasive or lack feasibility at the bedside with respect to 
time and availability. Imaging studies employing ultrasound, CT or MRI are limited but 
generally focus on morphological changes and muscle mass 4. In contrast, shear wave 
elastography (SWE), a relatively new ultrasound technology, offers the opportunity to 
evaluate a different method of evaluating muscle through its ability to objectively 
measure tissue stiffness 12. A role for SWE has previously been established for the 
management of various liver, thyroid and breast pathologies 12. Muscle stiffness 
increases proportionally with muscle force, and SWE have demonstrated reliable 
readings for determining this proportionality 13. It was also a sensitive biomarker in 
identifying patients with peripheral muscle weakness 14. 
Histological evidence supports a hypothesis of altered muscle stiffness in GIM 15, 
16. However, relatively little research has been conducted on muscle SWE and to our 
knowledge, there have been none in GIM. Moreover, limited research has evaluated a 
combined assessment of muscle mass, strength and performance as recommended in 
the diagnostic workup of GIM 10. Investigating the combination of these muscle 
aspects in patients taking high steroid doses could provide new insights into the 
mechanism of GIM development. Therefore, the main aim of this study was to 
investigate the responsiveness of muscle stiffness as measured by SWE and physical 
strength tests in patients exposed to high doses of glucocorticoid treatment.  
Patients and Methods 
 
 
 4 
Study design 
This study was conducted as a longitudinal cohort study at Leeds Teaching 
Hospitals in the UK between May 2017 to October 2018. Patients with giant cell 
arteritis were first seen up to 14 days post-treatment initiation (baseline (visit 1)) then 
followed up after three (visit 2) and six months (visit 3), with deviations of up to 15 
days allowed. These follow-up time points were selected based on the expected onset 
of early signs of myopathy 6. Patients were compared at baseline to age and gender 
frequency-matched healthy controls to evaluate their muscle characteristics. 
The study had been approved by the Nottingham UK research ethics committee 
(Reference: 17/EM/0079; approved April 2017) and written informed consent was 
obtained from all participants. No formal sample size/power calculations have been 
carried out due to a lack of available data. However, to estimate parameters for 
powering future research on GIM, published rules of thumb recommend a minimum of 
12 subjects per group of interest to provide a reasonable effect size estimate 17, 18.  
Patients 
The inclusion criteria for the patients were: 1- 50 years or older; 2- suspected or 
diagnosed with GCA as determined by the clinician, and fulfilling the American College 
of Rheumatology (ACR) classification criteria for GCA 19; 3- due to start or started (14 
days) on prednisolone (40mg/day). Exclusion criteria were: 1-presence or history of 
any muscle condition; 2- glucocorticoid treatment >5mg/day for more than three 
months in the past five years; 3-Taking glucocorticoids for a chronic obstructive 
pulmonary disease for more than six months in the past five years. Healthy controls 
were eligible if they were asymptomatic, not been treated with glucocorticoid at any 
dose in the past five years and did not have a history of any muscle condition. 
Patients were commenced on prednisolone 40–60 mg/day according to the 
established guidelines 20. The glucocorticoids were rapidly tapered to stop the 
treatment if the subsequent temporal biopsy results were negative and the clinical 
suspicion was not high. Otherwise, the patient continued on the glucocorticoid regimen 
and gradually tapered (unless relapse occurred) according to the management 
guidelines 20 as follows: 
1. Initial prednisolone dose (40–60 mg/day) continued for four weeks until 
resolution of symptoms and laboratory abnormalities. 
2. Dose reduced by 10 mg every two weeks to 20 mg. 
3. Then reduced by 2.5 mg every 2–4 weeks to 10 mg. 
4. Then reduced by 1 mg every 1–2 months provided there is no relapse. 
Clinical characteristics 
Relevant patient characteristics were collected including age, sex, body mass 
index (BMI). Additionally, muscle mass and fat mass were analyzed using a 
bioelectrical impedance analyzer [Tanita DC-430 MA (Tanita Europe B.V., 
Manchester, UK)]. Moreover, cumulative dose of glucocorticoids and mean daily 
dosage were noted. The previous and following variables were assessed at each visit.  
Shear wave elastography 
The operated SWE system was the two-dimensional Aixplorer (Supersonic 
Imagine, Aix-en-Provence, France) system using the SuperLinear™ SL10–-2MHz 
probe, which has demonstrated a substantial reliability in muscle SWE in our previous 
work 21. The principle of SWE is available elsewhere 12. Briefly, the ultrasound machine 
sends a strong acoustic pulse that deforms the tissue and induce the propagation of 
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relatively slow-travelling shear waves. The machine then sends tracking waves to 
detect the velocity of the shear eaves in meters/seconds (m/s), which can be used as 
a surrogate for tissue stiffness 12. The muscle SWE acquisition technique was adapted 
from our previous work 21-23. The probe was oriented along the muscle fibers and 
placed with minimal load on skin to avoid causing tissue deformation. 
The scanned muscles included the quadriceps [vastus lateralis (VL), rectus 
femoris (RF), vastus medialis (VM) and vastus intermedius (VI)], the hamstrings 
[biceps femoris (BF), semitendinosus (ST) and semimembranosus (SM)] and the 
biceps brachii (BB). Selecting these muscles was based on the evidence indicating 
GIM prevalence in the proximal thigh muscles 11. However, we also scanned the BB to 
test the involvement in upper body muscles. The muscles were scanned in a relaxed 
resting position with no active contraction. The quadriceps were also scanned with the 
knee flexed at 90 in a sitting position to assess the muscles’ passive elastic property. 
Only the dominant side was assessed due to time constraints and the previous 
evidence reporting pronounced muscle atrophy at the dominant leg in patients with 
GIM 24. 
Muscle strength measurements 
Isometric handgrip strength was measured while sitting using the handheld Jamar Plus+ 
electronic dynamometer (Lafayette Instrument Company, Lafayette, USA)] by calculating the 
average of three measurements of the dominant hand in units of kilogram-force (kgF) 
25. Next, 
the expanded timed get-up-and-go (ETGUG) test was conducted, which involves recording the 
time to stand from a chair, walk 10 meters, turn around, walk back and sit down 26. The 
participants then performed the 30-second chair stand test (maximum number of chair stands 
in 30 seconds) 27.  
Lastly, isokinetic concentric knee extension/flexion in the sitting position was tested using 
the Biodex system 4 (IRPS Mediquipe, UK). Previous evidence showed that this test 
demonstrated diminished strength in GIM 28. We chose to investigate concentric 
strength based on evidence showing that eccentric muscle strength can be preserved in 
diseases associated with sarcopenia and weakness 29. After warm-up of three sets at 50% 
effort, the participants performed three sets of three knee extension and flexion repetitions at 
100% effort separated by a 30 sec rest period between the sets at 60/sec angular velocity 30. 
The isokinetic strength outcomes of interest were the weight-normalised peak torque 
[Newton-meters (Nm)] to represent muscle strength (maximum force generated) and weight-
normalised average power (Watts) to represent muscle power (work done per unit of time) 
The trial runs before the final tests provided sufficient test familiarization. The 
participants were encouraged to perform their best during testing. 
Statistical analysis 
Descriptive statistics are expressed as frequencies for categorical data and as 
means (standard deviations) or medians for continuous data depending on the 
distribution. Independent sample t-test was employed to test for difference between 
healthy controls and patients at the baseline.  
The difference in SWV between the timepoints was correlated with the differences 
in muscle strength and functional tests using the Pearson’s correlation coefficients. 
This analyzed whether the longitudinal changes in SWV are associated with changes 
in muscle strength and function. The effect of cumulative glucocorticoid dose at 3 and 
6 months on SWV changes of each patient was plotted in a line chart. 
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The longitudinal data for the GCA patients were analyzed using linear mixed 
models to test if SWV significantly changes after three and six months of 
glucocorticoid treatment following previously described methods 31. The model was 
initially conducted as an unconditional base growth model then repeated in a second 
model after adding the time variable to determine if adding the follow-up visits will 
result in a significantly better model fit by comparing their -2 log likelihood (-2LL).  
The tests were conducted and reported on each muscle separately. Considering 
the small sample size, the data was also re-analysed using non-parametric methods 
and reported as supplementary material. The results showed the same findings as the 
parametric methods. We report the parametric results in the main text as our data 
satisfied the related assumptions and the fact that the same variables collected on a 
larger group were normally distributed 32. The tests were conducted and reported on 
each muscle separately. A n alpha level (p-value <0.05 was considered statistically 
significant. Statistical analysis was performed using SPSS version 25 (Armonk, NY: 
IBM Corp).   
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Results 
Seventy-nine patients with GCA were invited to take part in the study; 20 patients 
met the criteria and agreed to take part in the study; 6 were lost before the 3-month 
follow-up. Therefore, a total of 14 patients formed the basis of this study and were 
followed-up. The flowchart in Figure 1 highlights the recruitment timeline including the 
7 patients dropped out before the 6-months visit.  
The mean ± SD age ± SD of the GCA cohort was 68.2 ± 4.3 years (range 61.3–
76.5) with ten (71%) of the cohort being female. The patient characteristics and 
glucocorticoid information are listed in Table 1Table 1. They were recruited on average 
seven days (range -1 to 12 days) after commencing glucocorticoid treatment. The 
mean (SD, range) cumulative prednisolone dose was 2701 mg (619, 2280–4190) and 
4233 (926, 2962–5632) at 3 and 6 months respectively.  
Half of the patients had a positive temporal artery biopsy, one refused the 
procedure and the remaining six had a negative biopsy but were clinically diagnosed 
as GCA (strong clinical symptoms and rapid response to prednisolone). None of the 
patients complained of limb claudication. Two patients presented with symptoms of 
polymyalgia rheumatica (both had positive temporal biopsies). Two patients had 
hypertension, one had prostate hypertrophy and one had hypothyroidism. Additional 
prescribed medications included alendronic acid (n=7), omeprazole (n=3), Calceos 
(n=3), vitamin D (n=1), lansoprazole (n=1), aspirin (n=1), co-codamol (n=1) and 
levothyroxine (n=1).  
The patients and controls were frequency matched for age, sex, BMI and other 
body characteristics. In the muscle assessments, the GCA patients performed 
generally less well than controls; however, for most variables this difference did not 
reach statistical significance (supplementary table 1). 
Shear wave elastography 
The baseline SWE readings for the GCA patients were not significantly different 
from the healthy control group across all muscles (supplementary table 2). For the 
patients, the mean and differences in SWV between the visits are listed in Table 
2Table 2 (see supplementary table 3 for the non-parametric analysis). These results 
are graphically illustrated in the line charts for the muscles in the resting position in 
Figure 2-a and during passive stretching in Figure-2-b. In general, significant and 
consistent reductions were noted in the resting SWV measurements (Figure 2-a); the 
quadriceps readings under passive stretching showed greater variability (Figure 2-b).  
From baseline to 3 months, and to 6 months, there was a general reduction in 
SWV in all the leg muscles, but not in the arm muscle (biceps brachii). During the 
resting position in the quadriceps and hamstrings, SWV decreased by a mean of 14% 
(range 8.3% – 17.3%) after 3 months and 18% (range 10.2% – 25.3%) after 6 months 
(Table 2Table 2). SWE image examples from the quadriceps, hamstrings and BB are 
displayed in Figure 3. The two patients with PMR symptoms did not exhibit any 
different patterns compared to others. 
In the mixed linear models, adding the fixed effect of glucocorticoid consumption 
timepoints (baseline, 3-months and 6-months) had significant p-values for explaining 
longitudinal variations in SWV: p<0.005 in VL, p<0.001 in RF,  p=0.005 in VM, p<0.001 
in VI, p<0.001 in BF, p<0.001 in ST, p=0.001 in SM and p=0.028 in stretched VI. 
However, it did not explain a significant linear change in the BB (p=0.98), stretched VL 
(p=0.51), stretched RF (p=0.18) and stretched VM (p=0.18). The full list of the models 
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with the model fits (-2LL) and estimates for all muscles are provided in supplementary 
table 34.  
The cumulative steroid dose did not affect the magnitude of change in SWV. In 
other words, receiving a high cumulative glucocorticoid dose did not result in a greater 
change in SWV and vice versa. Profiles of relative change plotted as a function of 
cumulative glucocorticoid dose received for each patient can be reviewed in 
supplementary figure 1.  
Muscle assessments 
The longitudinal data for the muscle assessments are described in Table 3Table 3 
((see supplementary table 5 for the non-parametric analysis). The results show 
unremarkable fluctuations in body composition. Functional and strength performances 
remained generally similar to baseline. Pearson’s correlation coefficients were used to 
evaluate the association between SWV and muscle performance differences at the 3 
months follow-up visit. The difference at 3-months for the isokinetic knee extension 
strength correlated significantly with SWV differences in VL, VI and SM with 
coefficients (p-value) of 0.54 (0.048), 0.69 (0.006) and 0.60 (0.022) respectively. For 
the isokinetic knee extension power, the correlation coefficients (p-value) for the same 
muscles were 0.55 (0.041), 0.68 (0.007) and 0.50 (0.049) respectively. Weaker grip 
strength after 3-months correlated with lower SWV for ST (r=0.56; p=0.009). The 
correlation coefficients for changes between the other muscles and tests were 
generally weak (r <0.30) or insignificant (p >0.05). The full correlation results can be 
referred to in supplementary table 46 and 7. The small number of patients followed-up 
after 6 months (n=7) did not permit a meaningful correlation analysis as the 
coefficients can be easily influenced by outliers.  
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Discussion 
The aim of this study was to investigate muscle stiffness changes in patients 
receiving high doses of glucocorticoids after 3 and 6-months. To our knowledge, this is 
the first study to conduct this type of quantitative analysis. Half of the 14 recruited 
patients were lost in the last 6 months follow-up visit, where little subsequent drop in 
muscle stiffness was observed. The main result indicates that the proximal lower limb 
muscles of GCA patients can lose on average 15% and up to one-quarter of its 
stiffness after being exposed to high glucocorticoid dose therapy for 3 and 6-months. 
Additionally, this loss correlated with changes in muscle strength. However, the 
cumulative dose of glucocorticoids received either at 3 or 6 months was not related to 
the magnitude of the detected stiffness changes. The observed change in muscle 
stiffness might be explained by the microscopic morphological alterations induced by 
the catabolic and anti-anabolic effects of glucocorticoids on skeletal muscle 15, 16. 
No studies thus far have been conducted toThere is a lack of studies 
investigatinge the usefulness of SWE or similar imaging modalities for diagnosis or 
monitoring of GIM on humans. Nonetheless, the findings are in line with a recent 
preclinical study on rats, which demonstrated a significant reduction in muscle stiffness 
after glucocorticoid treatment 33. Their reported reduction of 10% is close to the mean 
change of 15% in this study regardless of the relatively different follow-up durations. 
They also stated that dosage (100ug/100g vs 50ug/100g) did not influence muscle 
stiffness which is in agreement with the presented results. 
A recent case study of Cushing’s syndrome myopathy suggested the usefulness 
of muscle echo intensity as a recovery sign after resolution of the hypercortisolemic 
state 34. Moreover, Nawata et al. 4 recently used computed tomography and showed a 
significant reduction in muscle mass (p=0.039) in a mixed group of patients taking 
glucocorticoids (>30 mg/day) for an average of three months. The usefulness of 
computed tomography, however, is complicated by the cost and exposure to ionizing 
radiation. 
For prolonged high-dose glucocorticoid exposure, the reported prevalence of GIM 
is remarkably variable in the literature ranging from 2% to 60% 2, 3, 24. In these studies, 
there was no significant muscle weakness observed in the follow-up visits suggestive 
of GIM. To the contrary, patients performed on average better after 3 and 6 months, 
except for the number of chair stands that decreased gradually at follow-up visits. 
Nawata et al. 4 also reported an improvement in muscle strength after 3-months of 
glucocorticoid treatment despite a significant reduction in muscle volume. 
In the present study, the changes in muscle strength were significantly associated 
with changes in muscle stiffness whereby patients who performed worse in the follow-
ups lost more muscle stiffness. At baseline, the patients presented with headache and 
pain due to the GCA symptoms and were generally feeling lethargic. This may have 
diminished their actual physical performance in the muscle assessments. Indeed, the 
self-reported general state of health rating (VAS scores in Table 3Table 3) improved 
gradually at the follow-ups. Furthermore, they performed on average worse than the 
healthy controls at baseline. It is possible that if the patients’ baseline muscle 
performance was normal, the correlations between SWV and muscle assessment 
differences would have been stronger and more consistent. It is worth noting that 
despite the age of the participants, it is unlikely that any of them has sarcopenia that 
could have affected the measurements, as the muscle strength and stiffness 
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measurements are appropriate for age when compared to a non-sarcopenic 
population 32. 
Steroid-induced atrophy seems to affect glycolytic fast-twitch fibers (i.e. type IIb) 
16. The BB has a high proportion (>60%) of type II fibers 35 compared to a balanced 
ratio in the quadriceps and hamstrings . This knowledge does not support the current 
results of preserved muscle stiffness in BB and diminished stiffness in quadriceps and 
hamstrings. The reason behind the differences is therefore not clear. Overall, the VL 
and BF demonstrated the least variability and most consistent significant changes 
between all time points. Moreover, the muscle stiffness changes were observed during 
resting and passive stretched positions. However, the readings variation during 
passive stretching was large, and the changes were less consistent compared to the 
resting position. 
Clinically, the tools to monitor or diagnose GIM are extremely limited and 
inadequate. EMG does not offer positive findings until late chronic stages of GIM 10. 
Muscle enzymes such as CK and aldolase usually appear within normal limits. Muscle 
biopsy can show signs of type IIb myofibre atrophy but is not feasible as a monitoring 
tool. No evidence has previously demonstrated the clinical usefulness for quantitative 
or qualitative MRI imaging in GIM.  
The clinical goal in GIM is to detect any myopathic changes prior to their 
manifestation to help taper the glucocorticoid dose promptly. This focuses on the 
prevention of GIM rather than identifying it at later stages when atrophy has occurred. 
The presented results highlight that the muscle strength loss was marginal compared 
to the SWV observed differences. This may suggest that muscle stiffness alterations 
may precede GIM symptoms of muscle weakness. 
The small sample size is acknowledged as a major limitation of the results. 
Additionally, half of the patients dropped out between 3 and 6 months. An attempt to 
improve the overall statistical power was made by employing multilevel modelling 
statistics 36. It was not feasible to study the patients before commencing treatment as 
the management guidelines recommend immediate start of glucocorticoids 20. Our aim 
was to follow-up the GCA cohort; hence the control group was only tested at the 
baseline to confirm the normal state of GCA muscles. We did not evaluate inter-
operator reproducibility. However, the decreasing trend observed on most muscles 
suggests that the changes were not merely due to day-to-day reading variability.  
Notwithstanding the above limitations, the promising findings call for future cohort 
studies to follow-up a larger sample of patients for a longer duration to assess if 
decreased muscle elasticity is a valid and reliable early sign for steroid-myopathy. To 
detect a 15% difference in the stiffness of VL after 3 months with 90% power and 0.05 
alpha level, a future study should aim to recruit a minimum of 63 GCA patients. 
Assuming the preliminary results are validated by other studies, SWE had the potential 
of being a non-invasive clinic-based tool for monitoring and detecting early signs of the 
glucocorticoid-induced myopathic process. Additionally, it may aid a physician’s 
decision to taper glucocorticoids more promptly. 
In conclusion, our results show that muscle stiffness measured by SWE may 
become significantly reduced in GCA patients receiving high doses of glucocorticoid 
after 3 and 6-months of treatment. Furthermore, higher reduction in muscle stiffness 
correlated with worse physical performance at the follow-up visits. Future research 
should study the results in a larger sample of patients for a longer duration to 
investigate if diminished muscle stiffness precedes GIM signs of muscle weakness.  
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Tables 
 
Table 1 Clinical and glucocorticoid dose information of the patients treated with 
prednisolone for giant cell arteritis. 
Case 
No Sex 
Age, 
years 
Starting 
dose, 
mg 
Daily 
dose 
at 
3m, 
mg 
Cumulative 
dose at 3m, 
mg 
Daily 
dose 
at 6m, 
mg 
Cumulative 
dose at 6m, 
mg 
1 Female 76.5 60 30 3935 7.5 5632 
2 Male 63.0 40 10 2280 1 2962 
3 Female 66.5 40 8 2723 10 4422 
4 Female 69.2 40 12.5 2415 - - 
5 Female 74.3 40 15 2543 7 3474 
6 Female 61.3 50 17.5 4190 - - 
7 Female 70.4 40 15 2690 10 3606 
8 Female 67.8 60 15 3850 9 4767 
9 Male 65.7 40 15 2990 - - 
10 Male 65.3 40 5 2375 - - 
11 Female 70.5 40 10 2712 - - 
12 Female 71.2 40 12.5 2528 17.5 4770 
13 Female 69.5 40 15 2680 - - 
14 Male 63.7 60 60 3080 - - 
3m= three months. 6m= six months. The dashes indicate data unavailability. 
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Table 2 Mean muscle shear wave velocity at each visit in the patients treated with glucocorticoids for giant cell arteritis. 
Muscle 
Baseline 3 Months (n=14) 6 Months (n=7) 
Mean (SD) 95% CI Mean (SD) 
95% 
CI 
Difference to 
baseline Mean (SD) 
95% 
CI 
Difference to 
3 months 
Difference to 
baseline 
Vastus lateralis 1.62 (0.16) 1.52, 
1.71 
1.40 (0.10) 1.35, 
1.46 
-0.22 (-13.6%) 
p<0.001 1.31 (0.06) 
1.26, 
1.36 
-0.09 (-6.4%) 
p=0.037 
-0.31 (-19.1%) 
p<0.001 
passively stretched 2.67 (0.33) 
2.46, 
2.88 2.66 (0.33) 
2.46, 
2.86 
-0.01 (-0.4%) 
p=0.96 2.50 (0.34) 
2.19, 
2.81 
-0.16 (-6%) 
p=0.91 
-0.17 (-6.4%) 
p=0.30 
Rectus femoris 1.68 (0.11) 1.62, 1.74 1.54 (0.13) 
1.47, 
1.62 
-0.14 (-8.3%) 
p=0.010 1.41 (0.15) 
1.28, 
1.55 
-0.13 (-8.4%) 
p=0.25 
-0.27 (-16.1%) 
p=0.002 
passively stretched 2.28 (0.63) 1.87, 
2.68 
1.99 (0.28) 1.82, 
2.16 
-0.29 (-12.7%) 
p=0.08 
2.05 (0.11) 1.95, 
2.15 
0.06 (3%) 
p=0.99 
-0.23 (-10.1%) 
p=0.16 
Vastus Medialis 1.70 (0.33) 
1.51, 
1.88 1.36 (0.12) 
1.29, 
1.43 
-0.34 (-20%) 
p=0.001 1.41 (0.15) 
1.27, 
1.55 
0.05 (3.7%) 
p=0.99 
-0.29 (-17.1%) 
p=0.012 
passively stretched 2.41 (0.28) 2.23, 
2.59 
2.30 (0.22) 2.17, 
2.43 
-0.11 (-4.6%) 
p=0.07 
2.30 (0.15) 2.16, 
2.43 
0 (0%)       
p=1.00 
-0.11 (-4.6%) 
p=0.18 
Vastus Intermedius 1.96 (0.33) 
1.77, 
2.15 1.62 (0.19) 
1.51, 
1.73 
-0.34 (-17.3%) 
p<0.001 1.76 (0.22) 
1.56, 
1.96 
0.14 (8.6%) 
p=0.030 
-0.20 (-10.2%) 
p=0.26 
passively stretched 2.42 (0.22) 2.28, 2.56 2.37 (0.34) 
2.16, 
2.58 
-0.05 (-2.1%) 
p=0.39 2.08 (0.34) 
1.77, 
2.39 
-0.29 (-12.2%) 
p=0.08 
-0.34 (-14%) 
p=0.013 
Biceps Brachii 1.83 (0.30) 1.66, 
2.01 
1.82 (0.18) 1.72, 
1.93 
-0.01 (-0.5%) 
p=0.94 
1.84 (0.28) 1.58, 
2.10 
0.02 (1.1%) 
p=0.99 
0.01 (0.5%) 
p=0.92 
Biceps Femoris 1.62 (0.17) 1.52, 1.72 1.37 (0.09) 
1.31, 
1.42 
-0.25 (-15.4%) 
p<0.001 1.21 (0.10) 
1.12, 
1.31 
-0.16 (-11.7%) 
p=0.022 
-0.41 (-25.3%) 
p<0.001 
Semitendinosus 1.58 (0.15) 1.49, 
1.66 
1.36 (0.08) 1.31, 
1.41 
-0.22 (-13.9%) 
p<0.001 1.26 (0.08) 
1.18, 
1.33 
-0.10 (-7.4%) 
p=0.043 
-0.32 (-20.3%) 
p<0.001 
Semimembranosus 1.59 (0.15) 
1.51, 
1.68 1.41 (0.11) 
1.34, 
1.47 
-0.18 (-11.3%) 
p<0.001 1.35 (0.10) 
1.26, 
1.44 
-0.06 (-4.3%) 
p=0.66 
-0.24 (-15.1%) 
p<0.001 
p-values computed using linear mixed models from the significance of difference estimates at 3 and 6-months.  p-values significant at 95% are in 
bold
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Table 3 Clinical and muscle assessment results at each visit for the patients treated with glucocorticoids for giant cell arteritis. 
Variable 
Baseline  3 Months (n=14)  6 Months (n=7) 
Mean (SD) Mean (SD) 
Difference to 
baseline Mean (SD) 
Difference to 3 
months 
Difference to 
baseline 
Weight (kg) 75.5 (16.8) 77.6 (16.4) 2.1 (2.8%) 75.2 (15.1) -2.4 (-3.1%) -0.3 (-0.4%) 
Body mass index (BMI) 27.1 (4.0) 27.9 (4.2) 0.8 (2.9%) 28.0 (4.3) 0.1 (0.3%) 0.9 (3.3%) 
Fat mass (kg) † 29.0 (13–31) 28.5 (21–31) -0.5 (-1.7%) 27.1 (22–32) -1.4 (-4.9%) -1.9 (-6.5%) 
Muscle mass (kg) † 45.0 (38–52) 46.6 (42–55) 1.6 (3.6%) 45.5 (41–47) -1.1 (-2.4%) 0.5 (1.1%) 
Muscle mass index 16.8 (1.8) 17.5 (2.1) 0.7 (4.2%) 17.3 (2.1) -0.2 (-1.1%) 0.5 (3.0%) 
Visual score of health (mm) † 25 (10–40) 19 (8–46) -6 (-24%) 15 (4–21) -4 (-21.0%) -10 (-40%) 
ETGUGT, Total time (sec) * 21.0 (5.7) 21.2 (6.3) 0.2 (0.9%) 19.3 (5.4) -1.9 (-9.0%) -1.7 (-8.1%) 
30 sec chair sit-to-stands 12.2 (6.5) 11.0 (4.5) -1.2 (-9.8%) 10.7 (2.4) -0.3 (-2.7%) -1.5 (-12.3%) 
Handgrip strength (kg) 25.9 (13.2) 26.7 (12.7) 0.8 (3.10%) 28.8 (11.3) 2.1 (7.9%) 2.9 (11.2%) 
Knee extension torque (Nm/kg) 1.03 (0.34) 1.04 (0.33) 0.01 (1.0%) 1.07 (0.40) 0.03 (2.9%) 0.04 (3.9%) 
Knee flexion torque (Nm/kg) 0.53 (0.22) 0.60 (0.25) 0.07 (13.2%) 0.63 (0.16) 0.03 (5.0%) 0.1 (18.9%) 
Knee extension power (W/kg) 0.57 (0.24) 0.56 (0.26) -0.01 (1.8%) 0.57 (0.24) 0.01 (1.8%) 0 (0%) 
Knee flexion power (W/kg) 0.29 (0.15) 0.34 (0.17) 0.05 (17.2%) 0.34 (0.09) 0 (0%) 0.05 (17.2%) 
† Median and interquartile range. * Other ETGUG test components had similar trends and were therefore omitted. 
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Figure legends 
Fig 1 A flowchart of participant screening, recruitment and follow-up 
 
Fig 2 Muscle stiffness changes in the GCA patients during the resting position (a) and 
for the quadriceps during passive stretching (b) 
 
Fig 3 Longitudinal shear wave elastography examples with velocity readings 
highlighting a significant reduction with time in the VL and VF compared to the 
insignificant change in BB 
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Supplementary material  
Supplementary Table 1. Demographics and baseline characteristics of the GCA 
patients and healthy controls. 
Characteristic GCA patients* Healthy controls* 
p-
value‡ 
Sex 
10 Females 
(71%) 10 Females (71%) 1.00 
Age (years) 68.2 (4.3) 68.0 (6.0) 0.91 
Height (cm) 166.3 (11.9) 163.8 (8.7) 0.53 
Weight (kg) 75.4 (16.8) 72.1 (9.7) 0.52 
Body mass index (BMI) 26.6 (4.3) 27.0 (4.5) 0.79 
Waist-hip ratio 0.90 (0.09) 0.90 (0.10) 0.95 
Fat mass † 28.9 (13.8–31.8) 27.3 (24.4–29.3) 0.66 
Muscle mass † 44.9 (37.7–52.0) 42.7 (38.6–44.2) 0.53 
Muscle mass index 16.8 (1.8) 17.0 (2.5) 0.83 
Ever smoked (yes) 7 (50%) 9 (64%) 0.44 
Smoking pack-years † 12.0 (7.5–45.0) 8.8 (2.0–33.0) 0.63 
Drinking alcohol 5 (35%) 5 (35%) 1.00 
consumption (units/week) † 2.0 (1.0–13.0) 10.0 (1.5–38.0) 0.07 
Visual analogue score of health 
(mm) † 
25 (10–40) 4.5 (1–18) 0.07 
ETGUGT, sit to stand (sec) 1.4 (0.4) 1.2 (0.4) 0.24 
ETGUGT, Gait initiation (sec) 1.1 (0.5) 0.9 (0.3) 0.37 
ETGUGT, Walk 1 (sec) 5.4 (1.6) 4.2 (1.0) 0.027 
ETGUGT, Turn around (sec) 3.8 (1.1) 3.4 (1.4) 0.44 
ETGUGT, Walk 2 (sec) 5.4 (1.6) 4.5 (1.0) 0.09 
ETGUGT, Slow, stop (sec) 3.2 (0.9) 2.8 (0.8) 0.16 
ETGUGT, Total time (sec) 21.0 (5.7) 17.0 (3.3) 0.038 
30 sec chair sit-to-stands 12.2 (6.5) 16.1 (3.9) 0.06 
Handgrip strength (kg) 25.9 (13.2) 29.7 (11.0) 0.42 
Knee extension torque (Nm/kg) 1.03 (0.33) 1.18 (0.33) 0.23 
Knee flexion torque (Nm/kg) 0.53 (0.21) 0.68 (0.22) 0.07 
Knee extension power (W/kg) 0.57 (0.24) 0.71 (0.18) 0.09 
Knee flexion power (W/kg) 0.29 (0.15) 0.40 (0.12) 0.032 
* Data presented as mean and standard deviation unless otherwise stated.  
† Median and interquartile range. 
‡ p-values significant at 95% are highlighted in bold. Continuous variables tested via 
independent t-test or Mann-Whitney, and categorical data tested using Chi-square 
test. 
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Supplementary table 2. Shear wave elastography readings at the baseline for the GCA patients compared to healthy. 
Muscle 
GCA patients Healthy controls 
Difference 
95% CI of the 
difference 
p-value‡ 
Mean* 95% CI Mean* 95% CI 
Vastus lateralis (VL) 1.62 (0.16) 1.52, 1.71 1.68 (0.20) 1.56, 1.79 0.06 -0.08, 0.20 0.39 
passively stretched 2.67 (0.33) 2.46, 2.88 2.80 (0.33) 2.60, 3.00 0.13 -0.14, 0.41 0.33 
Rectus femoris (RF) 1.68 (0.11) 1.62, 1.74 1.74 (0.15) 1.65, 1.83 0.06 -0.05, 0.16 0.28 
passively stretched 2.28 (0.63) 1.87, 2.68 2.19 (0.26) 2.03, 2.35 -0.09 -0.48, 0.31 0.66 
Vastus Medialis (VM) 1.70 (0.33) 1.51, 1.88 1.60 (0.18) 1.48, 1.71 -0.10 -0.31, 0.11 0.34 
passively stretched 2.41 (0.28) 2.23, 2.59 2.36 (0.21) 2.23, 2.49 -0.05 -0.25, 0.16 0.63 
Vastus Intermedius (VI) 1.96 (0.33) 1.77, 2.15 1.85 (0.11) 1.79, 1.92 -0.11 -0.30, 0.09 0.26 
passively stretched 2.42 (0.22) 2.28, 2.56 2.40 (0.28) 2.23, 2.57 -0.02 -0.23, 0.19 0.85 
Biceps Brachii (BB) 1.83 (0.3) 1.66, 2.01 1.87 (0.23) 1.74, 2.00 0.04 -0.17, 0.25 0.71 
Biceps Femoris (BF) 1.62 (0.17) 1.52, 1.72 1.65 (0.22) 1.52, 1.78 0.03 -0.12, 0.18 0.69 
Semitendinosus (ST) 1.58 (0.15) 1.49, 1.66 1.65 (0.24) 1.51, 1.78 0.07 -0.09, 0.22 0.37 
Semimembranosus (SM) 1.59 (0.15) 1.51, 1.68 1.58 (0.13) 1.51, 1.66 -0.01 -0.12, 0.10 0.81 
* Data in m/s with standard deviation. ‡ Results are based on independent sample t-test. 
Supplementary table 3. Median muscle shear wave velocity at each visit in the patients treated with glucocorticoids for giant cell arteritis. 
Muscle 
Baseline 3 Months (n=14) 6 Months (n=7) 
Median 
interquartile 
range 
Median 
interquartile 
range 
Difference to 
baseline 
Median 
interquartile 
range 
Difference to 3 
months 
Difference to 
baseline 
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Vastus lateralis 1.60 [1.52に1.73] 1.37 [1.33に1.43] -0.23 (-14.4%) 1.31 [1.29に1.35] -0.06 (-4.4%) -0.29 (-18.1%) 
passively stretched 2.65 [2.37に2.91] 2.67 [2.47に2.90] 0.02 (0.8%) 2.58 [2.44に2.69] -0.09 (-3.4%) -0.07 (-2.6%) 
Rectus femoris 1.68 [1.63に1.72] 1.49 [1.44に1.60] -0.19 (-11.3%) 1.42 [1.36に1.46] -0.07 (-4.7%) -0.26 (-15.5%) 
passively stretched 2.10 [1.90に2.22] 1.91 [1.82に2.09] -0.19 (-9%) 2.06 [2.05に2.12] 0.15 (7.9%) -0.04 (-1.9%) 
Vastus Medialis 1.70 [1.59に1.82] 1.37 [1.31に1.44] -0.28 (-17%) 1.37 [1.27に1.50] 0 (0%) -0.28 (-17%) 
passively stretched 2.41 [2.30に2.48] 2.24 [2.17に2.39] -0.17 (-7.1%) 2.28 [2.15に2.47] 0.04 (1.8%) -0.13 (-5.4%) 
Vastus 
Intermedius 
1.98 [1.74に2.16] 1.62 [1.51に1.73] -0.36 (-18.2%) 1.79 [1.64に1.99] 0.17 (10.5%) -0.19 (-9.6%) 
passively stretched 2.38 [2.21に2.65] 2.34 [2.16に2.54] -0.04 (-1.7%) 2.10 [1.78に2.37] -0.24 (-10.3%) -0.28 (-11.8%) 
Biceps Brachii 1.77 [1.65に1.92] 1.76 [1.70に1.86] -0.01 (-0.6%) 1.76 [1.63に1.97] 0 (0%) -0.01 (-0.6%) 
Biceps Femoris 1.60 [1.49に1.75] 1.37 [1.30に1.42] -0.23 (-14.4%) 1.27 [1.20に1.35] -0.1 (-7.3%) -0.33 (-20.6%) 
Semitendinosus 1.54 [1.42に1.69] 1.35 [1.31に1.38] -0.19 (-12.3%) 1.27 [1.24に1.30] -0.08 (-5.9%) -0.27 (-17.5%) 
Semimembranosus 1.58 [1.47に1.73] 1.37 [1.32に1.43] -0.21 (-13.3%) 1.34 [1.27に1.42] -0.03 (-2.2%) -0.24 (-15.2%) 
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Supplementary Table 34. Mixed linear models and fixed effect estimates for 
shear wave velocity on the various tested muscles. 
Vastus lateralis 
 Estimate (SE) 95% CI p-value 
Model 1: unconditional growth. 
Fit (-2LL)= -18.938    
Intercept 1.47 (0.03) 1.41, 1.53 <0.001 
Model 2: (time) 
Fit (-2LL)= -43.958 
〉 fit= 25.02 p-value= <0.001 
   
Intercept 1.62 (0.04) 1.52, 1.71 <0.001 
Time=baseline ref ref ref 
Time=3 months -0.21 (0.05) -0.31, -0.11 <0.001 
Time=6 months -0.30 (0.05) -0.41, -0.20 <0.001 
Time (type III test of fixed effect*) - - <0.001 
Rectus femoris 
 Estimate (SE) 95% CI p-value 
Model 1: unconditional growth. 
Fit (-2LL)= -25.294    
Intercept 1.57 (0.03) 1.52, 1.63 <0.001 
Model 2: (time) 
Fit (-2LL)= -36.027 
〉 fit= 10.73 p-value= <0.05 
   
Intercept 1.68 (0.03) 1.62, 1.74 <0.001 
Time=baseline ref ref ref 
Time=3 months -0.14 (0.05) -0.24, -0.04 0.010 
Time=6 months -0.27 (0.06) -0.41, -0.12 0.002 
Time (type III test of fixed effect) - - 0.002 
Vastus medialis 
 Estimate (SE) 95% CI p-value 
Model 1: unconditional growth. 
Fit (-2LL)= 12.248    
Intercept 1.50 (0.05) 1.41, 1.60 <0.001 
Model 2: (time) 
Fit (-2LL)= -11.718 
〉 fit= 23.97 p-value= <0.001 
   
Intercept 1.70 (0.09) 1.51, 1.88 <0.001 
Time=baseline ref ref ref 
Time=3 months -0.34 (0.08) -0.51, -0.16 0.001 
Time=6 months -0.28 (0.10) -0.49, -0.07 0.012 
Time (type III test of fixed effect) - - 0.005 
Vastus intermedius 
 Estimate (SE) 95% CI p-value 
Model 1: unconditional growth. 
Fit (-2LL)= 17.310    
Intercept 1.78 (0.05) 1.68, 1.89 <0.001 
Model 2: (time) 
Fit (-2LL)= -0.594 
〉 fit=17.9 p-value= <0.001 
   
Intercept 1.96 (0.09) 1.76, 2.16 <0.001 
Time=baseline ref ref ref 
Time=3 months -0.34 (0.07) -0.49, -0.18 <0.001 
Time=6 months -0.12 (0.10) -0.32, 0.09 0.26 
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Time (type III test of fixed effect) - - <0.001 
Biceps brachii 
 Estimate (SE) 95% CI p-value 
Model 1: unconditional growth. 
Fit (-2LL)= 5.630    
Intercept 1.83 (0.04) 1.74, 1.92 <0.001 
Model 2: (time) 
Fit (-2LL)= 7.819 
〉 fit=2.19 p-value= >0.05 
   
Intercept 1.83 (0.08) 1.65, 2.01 <0.001 
Time=baseline ref ref ref 
Time=3 months -0.01 (0.09) -0.2, 0.19 0.94 
Time=6 months 0.01 (0.13) -0.27, 0.30 0.92 
Time (type III test of fixed effect) - - 0.98 
Biceps femoris 
 Estimate (SE) 95% CI p-value 
Model 1: unconditional growth. 
Fit (-2LL)= -7.065    
Intercept 1.44 (0.03) 1.37, 1.51 <0.001 
Model 2: (time) 
Fit (-2LL)= -37.098 
〉 fit=30.03 p-value= <0.001 
   
Intercept 1.62 (0.05) 1.52, 1.72 <0.001 
Time=baseline ref ref ref 
Time=3 months -0.26 (0.05) -0.37, -0.14 <0.001 
Time=6 months -0.41 (0.06) -0.53, -0.29 <0.001 
Time (type III test of fixed effect) - - <0.001 
Semitendinosus 
 Estimate (SE) 95% CI p-value 
Model 1: unconditional growth. 
Fit (-2LL)= -19.407    
Intercept 1.42 (0.03) 1.37, 1.48 <0.001 
Model 2: (time) 
Fit (-2LL)= -48.795 
〉 fit=29.39 p-value= <0.001 
   
Intercept 1.58 (0.04) 1.50, 1.66 <0.001 
Time=baseline ref ref ref 
Time=3 months -0.22 (0.03) -0.30, -0.15 <0.001 
Time=6 months -0.34 (0.05) -0.44, -0.23 <0.001 
Time (type III test of fixed effect) - - <0.001 
Semimembranosus 
 Estimate (SE) 95% CI p-value 
Model 1: unconditional growth. 
Fit (-2LL)= -24.429    
Intercept 1.47 (0.03) 1.42, 1.53 <0.001 
Model 2: (time) 
Fit (-2LL)= -37.704 
〉 fit=13.28 p-value= <0.025 
   
Intercept 1.59 (0.04) 1.51, 1.68 <0.001 
Time=baseline ref ref ref 
Time=3 months -0.19 (0.04) -0.28, -0.09 0.001 
Time=6 months -0.24 (0.05) -0.35, -0.13 <0.001 
Time (type III test of fixed effect) - - 0.001 
Vastus lateralis (stretched) 
 Estimate (SE) 95% CI p-value 
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Model 1: unconditional growth. 
Fit (-2LL)= 21.913    
Intercept 2.63 (0.06) 2.51, 2.74 <0.001 
Model 2: (time) 
Fit (-2LL)= 24.783 
〉 fit=2.87 p-value= >0.05 
   
Intercept 2.67 (0.09) 2.46, 2.88 <0.001 
Time=baseline ref ref ref 
Time=3 months -0.01 (0.13) -0.28, 0.27 0.96 
Time=6 months -0.17 (0.16) -0.52, 0.17 0.30 
Time (type III test of fixed effect) - - 0.51 
Rectus femoris (stretched) 
 Estimate (SE) 95% CI p-value 
Model 1: unconditional growth. 
Fit (-2LL)= 40.455 
   
Intercept 2.11 (0.08) 1.95, 2.27 <0.001 
Model 2: (time) 
Fit (-2LL)= 17.862 
〉 fit= 22.59 p-value= <0.001 
   
Intercept 2.30 (0.17) 1.93, 2.67 <0.001 
Time=baseline ref ref ref 
Time=3 months -0.29 (0.15) -0.63, 0.04 0.08 
Time=6 months -0.25 (0.17) -0.62, 0.11 0.16 
Time (type III test of fixed effect) - - 0.18 
Vastus medialis (stretched) 
 Estimate (SE) 95% CI p-value 
Model 1: unconditional growth. 
Fit (-2LL)= 0.698    
Intercept 2.34 (0.04) 2.26, 2.42 <0.001 
Model 2: (time) 
Fit (-2LL)= -3.832 
〉 fit=4.53 p-value= >0.05 
   
Intercept 2.43 (0.08) 2.26, 2.59 <0.001 
Time=baseline ref ref ref 
Time=3 months -0.13 (0.07) -0.27, 0.01 0.07 
Time=6 months -0.12 (0.09) -0.3, 0.06 0.18 
Time (type III test of fixed effect) - - 0.18 
Vastus intermedius (stretched) 
 Estimate (SE) 95% CI p-value 
Model 1: unconditional growth. 
Fit (-2LL)= 20.815 
   
Intercept 2.33 (0.06) 2.21, 2.44 <0.001 
Model 2: (time) 
Fit (-2LL)= 8.673 
〉 fit=12.14 p-value= <0.05 
   
Intercept 2.42 (0.06) 2.29, 2.55 <0.001 
Time=baseline ref ref ref 
Time=3 months -0.07 (0.08) -0.23, 0.09 0.39 
Time=6 months -0.34 (0.11) -0.60, -0.09 0.013 
Time (type III test of fixed effect) - - 0.028 
-2LL= −2 restricted log-likelihood (estimate of the model fit displayed in smaller-is-
better form). SE= standard error. * Omnibus test of significance for the time variable. 〉 
fit= change in model fit [significance determined comparing the 〉 fit value to the chi-
square statistic critical values for 0.001 (99%), 0.025 (97.5%) and 0.05 (95%)].  
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Supplementary table 5. Clinical and muscle assessment results at each visit for the patients treated with glucocorticoids for giant cell 
arteritis (presented as medians). 
Variable Baseline  3 Months (n=14)  6 Months (n=7) 
 Median [IQR] Median [IQR] 
Difference to 
baseline 
Median [IQR] 
Difference to 3 
months 
Difference to 
baseline 
Weight (kg) 75.1 [63.0に88.5] 75.3 [63.8に92.4] 0.2 (0.27%) 75.2 [60.7に82.3] -0.1 (-0.13%) 0.1 (0.13%) 
Body mass index (BMI) 27.9 [24.0に30.2] 27.4 [23.4に30.7] -0.5 (-1.79%) 29.0 [25.3に31.9] 1.6 (5.84%) 1.1 (3.94%) 
Fat mass (kg) 28.9 [13.7に31.9] 28.5 [19.5に31.4] -0.4 (-1.38%) 27.1 [21.0に33.1] -1.4 (-4.91%) -1.8 (-6.23%) 
Muscle mass index 29.0 [13に31] 28.5 [21に31] -0.5 (-1.7%) 27.1 [22に32] -1.4 (-4.9%) -1.9 (-6.5%) 
Muscle mass (kg) 45.0 [38に52] 46.6 [42に55] 1.6 (3.6%) 45.5 [41に47] -1.1 (-2.4%) 0.5 (1.1%) 
Visual score of health (mm) 25 [10に40] 19 [8に46] -6 (-24%) 15 [4に21] -4 (-21.0%) -10 (-40%) 
ETGUGT, Total time (sec)* 21.3 [17.5に25.5] 20.7 [18.1に24.2] -0.6 (-2.82%) 19 [13.4に24.0] -1.7 (-8.21%) -2.3 (-10.8%) 
30 sec chair sit-to-stands 12 [8.7に14.5] 11 [8.7に14.2] -1 (-8.33%) 11 [8.5に12.5] 0 (0%) -1 (-8.33%) 
Handgrip strength (kg) 24.0 [18.2に35.5] 24.0 [18.4に34.6] 0 (0%) 27.1 [22.0に34.0] 3.1 (12.92%) 3.1 (12.92%) 
Knee extension torque (Nm/kg) 0.95 [0.81に1.29] 0.98 [0.80に1.27] 0.03 (3.16%) 1.00 [0.80に1.54] 0.02 (2.04%) 0.05 (5.26%) 
Knee flexion torque (Nm/kg) 0.51 [0.35に0.75] 0.60 [0.40に0.74] 0.09 (17.65%) 0.61 [0.53に0.73] 0.01 (1.67%) 0.1 (19.61%) 
Knee extension power (W/kg) 0.55 [0.35に0.75] 0.53 [0.40に0.74] -0.02 (-3.64%) 0.53 [0.53に0.73] 0 (0%) -0.02 (-3.64%) 
Knee flexion power (W/kg) 0.30 [0.20に0.39] 0.35 [0.27に0.43] 0.05 (16.67%) 0.35 [0.28に0.40] 0 (0%) 0.05 (16.67%) 
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Supplementary Table 46. Correlation coefficients for the associations between 
SWV and muscle performance differences at the 3 months follow-up visit. 
  
VL RF VM VI BF ST SM 
ETGUGT Total 
time 
Coefficient -.280 -.121 -.008 -.076 .100 -.207 -.037 
p-value .332 .681 .979 .796 .734 .478 .901 
Number of chair 
sit to stands in 
30 sec 
Coefficient .307* .346* -.039 .092 -.107 .172 .447* 
p-value .286 .225 .895 .755 .715 .556 .109 
Handgrip 
strength 
Coefficient .429* .417* .184 .112 .206 .559* .111 
p-value .126 .138 .529 .703 .479 .038 .706 
Isokinetic peak 
torque extension 
Coefficient .535** .293 .452* .692** .38 .450* .606* 
p-value .048 .309 .105 .006 .180 .106 .022 
Isokinetic peak 
torque flexion 
Coefficient -.043 .135 .149 .383* .382* .372* .193 
p-value .884 .645 .61 .177 .178 .191 .508 
Isokinetic mean 
power extension 
Coefficient .552** .284 .394* .682** .411* .26 .501** 
p-value .041 .326 .164 .007 .144 .369 .049 
Isokinetic mean 
power flexion 
Coefficient .059 .384* .297 .584** .594* .504** .329* 
p-value .842 .175 .302 .028 .025 .066 .250 
*  low correlation (r=0.30–0.49) 
** moderate correlation  (r=0.50–0.70) 
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Supplementary table 7. Spearman’s rho correlation coefficients for the 
associations between SWV and muscle performance differences at the 3 months 
follow-up visit. 
 
  
VL RF VM VI BF ST SM 
ETGUGT 
Total time 
Coefficient -.22 .059 .068 -.02 .002 -.349 -.086 
p-value .45 .84 .817 .946 .994 .221 .771 
Number of 
chair sit to 
stands in 30 
sec 
Coefficient .334 .169 .062 .073 .071 .364 .389 
p-value .244 .564 .833 .803 .809 .20 .169 
Handgrip 
strength 
Coefficient .095 
-
.033 .015 -.143 .064 .523* .108 
p-value .748 .911 .958 .626 .829 .41 .714 
Isokinetic 
peak torque 
extension 
Coefficient .455 .196 .433 .723** .354 .376 .582* 
p-value .102 .503 .122 .003 .215 .185 .029 
Isokinetic 
peak torque 
flexion 
Coefficient -.018 .174 .051 .323 .349 .279 .187 
p-value .952 .553 .864 .26 .221 .334 .523 
Isokinetic 
mean power 
extension 
Coefficient .601* .305 .516 .705** .31 .196 .459 
p-value .023 .288 .059 .005 .281 .503 .098 
Isokinetic 
mean power 
flexion 
Coefficient .152 .451 .262 .622* .520* .433 .512 
p-value .604 .106 .366 .018 .49 .122 .061 
*  low correlation (r=0.30–0.49) 
** moderate correlation  (r=0.50–0.70) 
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Supplementary Figure 1. Change in shear wave velocity relative to the total 
cumulative dose received (grams) for each patient at 3 (a) and 6 (b) months. 
The SWV value at the follow-up visits was subtracted from the baseline visit to give the 
relative change in SWV relative to baseline. These SWV difference values were then 
subtracted from the total cumulative dose (divided by 1000 to be in grams). This allows us to 
see the profile of the changes in SWV, and compare these according to how much total 
steroid the patient had; they start from their cumulative steroid dose and change by the 
amount their SWV changed over time. 
 
